Now published! FT3 perspective piece calling for a new intersectoral collaborative approach for better patient outcomes. Discover it here
Who we are
The From Testing to Targeted Treatment Program (FT3), founded in 2020, is a global non-profit initiative focused on making precision medicine accessible to all who need it.
FT3 fosters collaboration among patients, healthcare professionals, and industry stakeholders to drive sustainable change through shared leadership and decision-making.
A global multi-stakeholder precision medicine accelerator​
Co-led by patients
Shared decision making and solution building across diverse stakeholder groups
Bringing together and building on existing learnings and good practices
Starting with testing and cancer
FT3 is a global accelerator of change, working together with diverse stakeholders to identify common gaps, scale good practices and defragment efforts in precision medicine. Our goal is to share and support local good practices and build a backbone of expertise and practical resources that are designed to be adapted to support patient organizations and other precision medicine champions on the ground.
Project Team
Membership
Our shared leadership approach
Quotes from members
I believe that this is the first and only global coalition to address this issue by bringing patients, advocates, pharma and diagnostic companies, HCPs, payers, and regulators who will all work together to establish best practices to make personalized care accessible to all people.
Susan McClure
Genome Creative
This multi-stakeholder non-profit initiative has a strong focus on patients' needs and strong backing within industry, this makes for a very good start to create sustainable projects and ultimately lasting value.
Dr. Benedikt Westphalen
Comprehensive Cancer Centre, University of Munich